Scintigraphic Evaluation of Lymphoma: A Comparative Study of67Ga-Citrate and111ln-Bleomycin

Publisher Website
Google Scholar
Abstract
Sequential whole body scans with 67Ga-citrate and 111In-bleomycin were performed for 14 patients undergoing staging for Hodgkin''s disease or other lymphomas. A comparison of these scans gave a sensitivity in detecting the pathologically proved tumor sites of 84% for 67Ga-citrate and only 56% for 111In-bleomycin. In 12 patients, the Ga scan demonstrated the lesions more clearly. In the others, the uptake of the 2 radionuclides was equal. In no case was a clinically diagnosed or histologically proved lesion identified by 111In-bleomycin that was not also demonstrated by 67Ga-citrate. 111In-bleomycin does not complement the 67Ga-citrate scan in the scintigraphic evaluation of lymphomas.